β2‐Glycoprotein I‐derived peptides as antigenic structures for the detection of antiphospholipid antibodies

Müller, Carolin; Thaler, Markus; Schlichtiger, Alice; Schreiegg, Anita; Balling, G.; Steigerwald, Udo; Luppa, Peter B.

doi:10.1111/j.1538-7836.2010.03987.x

Cited by 5 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found no differences in inhibition between patient/control samples for both peptides in contrast to inhibition with domain I and concluded that triple aPL-positive patients have a significantly higher titer of anti-domain I antibodies as compared to double or single aPL-positive patients [38]. Another study with domains I-V of b2GPI-specific peptides (including elongated peptides A-C) was conducted by Muller et al [39] on a surface plasmon resonance (SPR) biosensor system. No differences between 21 serum samples from APS patients and age-/sex-matched controls were detected in SPR signals for all peptides [39], in contrast to higher SPR responses for patient serum samples compared with controls when immobilized b2GPI was used [40], indicating a problem in detection of antibody binding to short amino acid sequences.…”

Section: Discussionmentioning

confidence: 92%

“…Another study with domains I-V of b2GPI-specific peptides (including elongated peptides A-C) was conducted by Muller et al [39] on a surface plasmon resonance (SPR) biosensor system. No differences between 21 serum samples from APS patients and age-/sex-matched controls were detected in SPR signals for all peptides [39], in contrast to higher SPR responses for patient serum samples compared with controls when immobilized b2GPI was used [40], indicating a problem in detection of antibody binding to short amino acid sequences. Zager et al [26] used SPR chips with immobilized b2GPI and noted that antibodyantigen interactions between polyclonal HAv IgG antib2GPI and b2GPI are presumably more stable, monovalent and less dependent on antigen density as compared to polyclonal LAv IgG anti-b2GPI, which form less stable complexes, are more dependent on antigen density and require bivalent interactions.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I

Artenjak¹,

Locatelli

Brelih

et al. 2014

Immunol Res

View full text Add to dashboard Cite

The pathogenicity of antibodies against β2-glycoprotein I (anti-β2GPI) depends on multiple factors such as subclass type, epitope binding and avidity. Due to their large heterogeneity, their impact on antiphospholipid syndrome (APS) onset is still not fully clarified. We studied the binding characteristics of IgG anti-β2GPI with known avidity from sera of 201 autoimmune patients (87 with APS, 67 with APS associated with systemic lupus erythematosus (SLE), 47 with only SLE) to six β2GPI peptides corresponding to amino acid clusters on domains I-II, II, III and III-IV by indirect ELISA and evaluated their association with clinical features of APS. Peptides A (LKTPRV; domain I-II), B (KDKATF; domain IV) and C (TLRVYK; domain III) were derived from a hexapeptide phage display library previously shown to react with pathogenic monoclonal anti-β2GPI. Peptides D (NGPANSK; domain III), E (YNPLWFV; domain II) and F (KMDGNHP; domain III-IV) represent surface amino acid clusters on β2GPI. The percentage of patients positive for peptides were observed as follows: 30.3% for peptide D, 28.90% for B, 25.9% for C, 24.9% for E, 24.4% for F and 10.0% for A. The anti-peptide antibodies in studied serum samples were predominantly of heterogeneous avidity, followed by law avidity anti-peptide antibodies, whereas only a few were of high avidity. Positive and negative correlations were found between several anti-peptide antibodies and the rate of thrombosis. Our results indicated diverse reactivity of IgG anti-β2GPI to different epitopes on β2GPI. Classification of IgG anti-β2GPI into subgroups regarding epitope specificity and avidity could represent an additional tool in understanding their pathogenicity in APS.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I

Artenjak¹,

Locatelli

Brelih

et al. 2014

Immunol Res

View full text Add to dashboard Cite

show abstract

“…We have chosen a modification based on the short silane 11-AUTMS that forms a two-dimensional surface on the glass transducer. This only allows a low density of immobilized antigen but Brought to you by | Purdue University Libraries Authenticated Download Date | 5/28/15 8:28 PM [9,21,22]. Also for the 1-λ-reflectometry, this surface modification allowed a selective and sensitive discrimination of APS patients from healthy controls.…”

Section: Discussionmentioning

confidence: 96%

Diagnostic performance study of an antigen microarray for the detection of antiphospholipid antibodies in human serum

Schindler

Bleher

Thaler

et al. 2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…In the same year, the authors also demonstrated that the employment of β2-GPI-derived domain-specific peptides would have offered diagnostic advantages in primary autoantibody screening for APS and in discrimination of sera of APS patients from sera of healthy patients [77].…”

Section: Antibodies For Immune Disordersmentioning

confidence: 98%

Surface plasmon resonance applications in clinical analysis

2014

View full text Add to dashboard Cite

In the last 20 years, surface plasmon resonance (SPR) and its advancement with imaging (SPRi) emerged as a suitable and reliable platform in clinical analysis for label-free, sensitive, and real-time monitoring of biomolecular interactions. Thus, we report in this review the state of the art of clinical target detection with SPR-based biosensors in complex matrices (e.g., serum, saliva, blood, and urine) as well as in standard solution when innovative approaches or advanced instrumentations were employed for improved detection. The principles of SPR-based biosensors are summarized first, focusing on the physical properties of the transducer, on the assays design, on the immobilization chemistry, and on new trends for implementing system analytical performances (e.g., coupling with nanoparticles (NPs). Then we critically review the detection of analytes of interest in molecular diagnostics, such as hormones (relevant also for anti-doping control) and biomarkers of interest in inflammatory, cancer, and heart failure diseases. Antibody detection is reported in relation to immune disorder diagnostics. Subsequently, nucleic acid targets are considered for revealing genetic diseases (e.g., point mutation and single nucleotides polymorphism, SNPs) as well as new emerging clinical markers (microRNA) and for pathogen detection. Finally, examples of pathogen detection by immunosensing were also analyzed. A parallel comparison with the reference methods was duly made, indicating the progress brought about by SPR technologies in clinical routine analysis.

show abstract

β2‐Glycoprotein I‐derived peptides as antigenic structures for the detection of antiphospholipid antibodies

Cited by 5 publications

References 11 publications

Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I

Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I

Diagnostic performance study of an antigen microarray for the detection of antiphospholipid antibodies in human serum

Surface plasmon resonance applications in clinical analysis

Contact Info

Product

Resources

About